S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News

$5.54
-0.44 (-7.36 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$5.52
Now: $5.54
$6.12
50-Day Range
$5.15
MA: $6.00
$6.84
52-Week Range
$3.42
Now: $5.54
$9.37
Volume66,203 shs
Average Volume71,997 shs
Market Capitalization$116.44 million
P/E RatioN/A
Dividend YieldN/A
Beta3.1
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$4.18 per share

Profitability

Net Income$-9,860,000.00

Miscellaneous

Employees17
Market Cap$116.44 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.


Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

6 Wall Street analysts have issued 1 year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $10.00 to $28.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $19.00 in the next year. This suggests a possible upside of 243.0% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

What is the consensus analysts' recommendation for Galmed Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

Has Galmed Pharmaceuticals been receiving favorable news coverage?

News headlines about GLMD stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Galmed Pharmaceuticals.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Rite Aid (RAD), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Immunomedics (IMMU), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), SCYNEXIS (SCYX) and Verastem (VSTM).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
  • Mr. Yohai Stenzler, CFO & Controller (Age 36)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 34)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 49)

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.92%), Voss Capital LLC (0.72%), P.A.W. Capital Corp (0.48%), ARK Investment Management LLC (0.43%), Renaissance Technologies LLC (0.31%) and Phoenix Holdings Ltd. (0.09%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd..

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was acquired by a variety of institutional investors in the last quarter, including Voss Capital LLC, Raymond James & Associates, Renaissance Technologies LLC, P.A.W. Capital Corp, ARK Investment Management LLC and Tower Research Capital LLC TRC .

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $5.54.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $116.44 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.


MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel